Cell Reports (Aug 2016)
Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer
- Adam Shlien,
- Keiran Raine,
- Fabio Fuligni,
- Roland Arnold,
- Serena Nik-Zainal,
- Serge Dronov,
- Lira Mamanova,
- Andrej Rosic,
- Young Seok Ju,
- Susanna L. Cooke,
- Manasa Ramakrishna,
- Elli Papaemmanuil,
- Helen R. Davies,
- Patrick S. Tarpey,
- Peter Van Loo,
- David C. Wedge,
- David R. Jones,
- Sancha Martin,
- John Marshall,
- Elizabeth Anderson,
- Claire Hardy,
- Violetta Barbashina,
- Samuel A.J.R. Aparicio,
- Torill Sauer,
- Øystein Garred,
- Anne Vincent-Salomon,
- Odette Mariani,
- Sandrine Boyault,
- Aquila Fatima,
- Anita Langerød,
- Åke Borg,
- Gilles Thomas,
- Andrea L. Richardson,
- Anne-Lise Børresen-Dale,
- Kornelia Polyak,
- Michael R. Stratton,
- Peter J. Campbell
Affiliations
- Adam Shlien
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- Keiran Raine
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- Fabio Fuligni
- Department of Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
- Roland Arnold
- Department of Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
- Serena Nik-Zainal
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- Serge Dronov
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- Lira Mamanova
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- Andrej Rosic
- Department of Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
- Young Seok Ju
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- Susanna L. Cooke
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- Manasa Ramakrishna
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- Elli Papaemmanuil
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- Helen R. Davies
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- Patrick S. Tarpey
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- Peter Van Loo
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- David C. Wedge
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- David R. Jones
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- Sancha Martin
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- John Marshall
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- Elizabeth Anderson
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- Claire Hardy
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- Violetta Barbashina
- Breakthrough Breast Cancer, The Institute of Cancer Research, London SM2 5NG, UK
- Samuel A.J.R. Aparicio
- British Columbia Cancer Agency, Vancouver, BC V5Z 1L3, Canada
- Torill Sauer
- Department of Pathology, Oslo University Hospital, 0450 Oslo, Norway
- Øystein Garred
- Department of Pathology, Oslo University Hospital, 0450 Oslo, Norway
- Anne Vincent-Salomon
- Institut Curie, 75005 Paris, France
- Odette Mariani
- Institut Curie, 75005 Paris, France
- Sandrine Boyault
- Synergie Lyon Cancer, Centre Léon Bérard, 69008 Lyon, France
- Aquila Fatima
- Dana-Farber Cancer Institute, Boston, MA 02215, USA
- Anita Langerød
- Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0379 Oslo, Norway
- Åke Borg
- Department of Oncology, Lund University, SE-221 00 Lund, Sweden
- Gilles Thomas
- Synergie Lyon Cancer, Centre Léon Bérard, 69008 Lyon, France
- Andrea L. Richardson
- Dana-Farber Cancer Institute, Boston, MA 02215, USA
- Anne-Lise Børresen-Dale
- Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0379 Oslo, Norway
- Kornelia Polyak
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
- Michael R. Stratton
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- Peter J. Campbell
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK
- DOI
- https://doi.org/10.1016/j.celrep.2016.07.028
- Journal volume & issue
-
Vol. 16,
no. 7
pp. 2032 – 2046
Abstract
Disordered transcriptomes of cancer encompass direct effects of somatic mutation on transcription, coordinated secondary pathway alterations, and increased transcriptional noise. To catalog the rules governing how somatic mutation exerts direct transcriptional effects, we developed an exhaustive pipeline for analyzing RNA sequencing data, which we integrated with whole genomes from 23 breast cancers. Using X-inactivation analyses, we found that cancer cells are more transcriptionally active than intermixed stromal cells. This is especially true in estrogen receptor (ER)-negative tumors. Overall, 59% of substitutions were expressed. Nonsense mutations showed lower expression levels than expected, with patterns characteristic of nonsense-mediated decay. 14% of 4,234 rearrangements caused transcriptional abnormalities, including exon skips, exon reusage, fusions, and premature polyadenylation. We found productive, stable transcription from sense-to-antisense gene fusions and gene-to-intergenic rearrangements, suggesting that these mutation classes drive more transcriptional disruption than previously suspected. Systematic integration of transcriptome with genome data reveals the rules by which transcriptional machinery interprets somatic mutation.